Pliant Therapeutics Inc (PLRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.82-4.23%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · PLRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 83.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
PLRX — director transition
Dated 2026-07-13
Director — Robert Iannone, M.D., M.S.C.E. and Flavia Borellini, Ph.D.: The Board of Directors appointed two new directors to fill newly-created vacancies and expanded their roles within the company.
Why it matters: The platform is still in early tests. Positive results could show it can deliver drug payloads to chosen tissues.
Supportive ifPliant reports a positive early test of a payload, such as siRNA, carried by integrins.
Worry ifPliant reports failed early tests or stops work on the delivery platform.
Why it matters: The company reported $172.4 million in cash and investments. A shorter funding range could raise pressure to cut costs or raise funds.
Worry ifPliant reports cash and short-term investments below $150 million, or cuts its funding range to end before the second half of 2028.
Less concerning ifPliant keeps its funding range into the second half of 2028 and reports cash and short-term investments at or above $150 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$177 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $444 loss on $10,000 · 4.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,145 loss on $10,000 · 31.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.